Novo Nordisk GLP-1 fails to slow Alzheimer's in 2 trials
Digest more
The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review ...
Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The ...
Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations ...
While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...
AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) was approved in the U.S. for the treatment of adult ...
Discover why Novo Nordisk’s stagnating growth and lower obesity drug efficacy may signal more downside risk for investors.
And one of them is pharmaceutical giant Pfizer ( PFE +1.98%). Now, with a major step along the path to entering this ...
Novo Nordisk is filing its supplemental new drug application (sNDA) for Wegovy 7.2 mg on the back of the phase 3b STEP UP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback